DrugForm-DTA: Towards real-world drug-target binding Affinity Model
Ivan KhokhloviD, Anna S. TashchilovaiD, Nikolai Bugaev-Makarovskiy, Olga Valentinovna GlushkovaiD, Vladimir Sergeevich YudiniD, Anton Arturovich KeskinoviD, Sergey Mikhailovich YudiniD, Dmitry Vladimirovich SvetlichnyyiD, Veronika Igorevna SkvortsovaiD
Abstract
Drug-target affinity (DTA) prediction is a fundamental problem in drug discovery. Computational methods for predicting DTA can greatly assist drug design by decreasing the search space and reducing the number of protein-ligand complexes with low affinity. Currently DTA approaches often do not require protein three-dimensional (3D) structural information, which is often not accessible. In this study we present the DrugForm-DTA model, which uses only structure-less representations of ligand and protein. It is a Transformer-based neural network with protein encoding based on ESM, and small molecule ligand encoding obtained with Chemformer. We evaluated the model on standard benchmarks Davis and KIBA, and revealed superior performance of DrugForm-DTA with best result for KIBA (MSE=0.117). Moreover, we developed a ready-to-use model using BindingDB dataset that was subjected to high-quality filtering and transformation. Overall, our method predicts drug-target affinity values with a confidence level comparable to a single in-vitro experiment. Also, we compared DrugForm-DTA against molecular modeling methods and revealed higher efficacy of the developed model for drug-target affinity predictions. Our investigation provides a high accuracy neural network model with performance comparable to experi-mental measurements, filtered and reassessed BindingDB dataset for further usage, and demonstrates outstanding applicability of the proposed method for DTA prediction. Author summaryPredicting drug-target binding affinity is a crucial task in computational drug discovery. Here we present DrugForm-DTA, a ready-to-use Transformer-based model which requires only protein amino acid sequence and ligand SMILES as inputs. The model shows excellent results at commonly used benchmarks. We believe that the success in solving machine learning tasks depends on data quality and quantity, so the main focus of our work is the training data, but not a sophisticated neural architecture. We used BindingDB database as the source of experimental affinity measurements and prepared a refined and purified dataset, suitable for training machine learning models. Trained on this dataset, the DrugForm-DTA model demonstrates accuracy, comparable to a single in-vitro experiment. We also reveal that our model outperforms molecular modeling methods in estimating binding affinity. Both the prepared dataset and the trained model is published and freely available.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 7
- FWCI
- 3.62
- Field percentile
- top 6%
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Drug-Target Binding Affinity Prediction Using Transformers
Mahsa Saadat, Armin Behjati, … Sajjad Gharaghani·bioRxiv·Sep 30, 2021
- MMD-DTA: A multi-modal deep learning framework for drug-target binding affinity and binding region prediction
- Sequence-Driven Drug-Target Affinity Prediction Via Graph Attention Networks and Bidirectional Cross-Attention Fusion
Zakeerhussain D Kudari, Virendra Singh Kaira, … Jaiganesh G·bioRxiv·Apr 6, 2026
- 3DProtDTA: the deep learning model for drug-target affinity prediction based on the residue-level protein graphs
T. Voitsitskyi, R. Stratiichuk, … S. Starosyla·bioRxiv·Nov 24, 2022
- CASTER-DTA: Equivariant Graph Neural Networks for Predicting Drug-Target Affinity
Rachit Kumar, Joseph D. Romano, Marylyn DeRiggi Ritchie·Briefings in BioinformaticsPeer-reviewed·Aug 31, 2025
- BindingSiteAugmentedDTA: Enabling A Next-Generation Pipeline for Interpretable Prediction Models in Drug-Repurposing
Niloofar Yousefi, Mehdi Yazdani-Jahromi, … Özlem Özmen Garibay·Briefings in BioinformaticsPeer-reviewed·Apr 24, 2023